Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21660
10.3322/caac.21660 · External reference
10.3322/caac.21754
10.3322/caac.21754 · External reference
Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update
10.1200/jco.22.00069 · 2022 · External reference
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
10.1016/j.annonc.2021.06.023 · 2021 · External reference
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?
10.1016/j.ctrv.2022.102445 · 2022 · External reference
10.1001/jama.2018.19323
10.1001/jama.2018.19323 · External reference
Breast surgery: management of postoperative complications following operations for breast cancer
10.1016/j.suc.2021.06.014 · 2021 · External reference
Lymphedema after breast cancer treatment
10.1056/nejmcp1803290 · 2018 · External reference
Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries
10.1002/ijc.32908 · 2020 · External reference
The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients
10.1038/s41523-020-0161-3 · 2020 · External reference
10.1016/s0140-6736(20)32381-3
10.1016/s0140-6736(20)32381-3 · External reference
10.1038/s41591-018-0014-x
10.1038/s41591-018-0014-x · External reference
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
10.1186/s13045-021-01103-4 · 2021 · External reference
Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35
10.1038/s41388-021-02091-y · 2022 · External reference
Innate immune cells in the tumor microenvironment
10.1016/j.ccell.2021.05.016 · 2021 · External reference
Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer
10.7150/jca.35901 · 2019 · External reference
10.1186/s13045-019-0798-2
10.1186/s13045-019-0798-2 · External reference
10.1038/s41392-022-01136-2
10.1038/s41392-022-01136-2 · External reference
10.1126/science.abf0529
10.1126/science.abf0529 · External reference
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
10.1158/0008-5472.can-20-0471 · 2020 · External reference
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
2018 · External reference
Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis
2020 · External reference
10.1016/j.compbiomed.2022.105924
10.1016/j.compbiomed.2022.105924 · External reference
Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma
10.1186/s13062-023-00358-w · 2023 · External reference
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis
10.1186/s12943-023-01752-8 · 2023 · External reference
10.1073/pnas.0610618104
10.1073/pnas.0610618104 · External reference
Downregulation of dihydrolipoyl dehydrogenase by UVA suppresses melanoma progression via triggering oxidative stress and altering energy metabolism
10.1016/j.freeradbiomed.2020.11.037 · 2021 · External reference
Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer
10.1038/s41598-022-22300-2 · 2022 · External reference
Pan-cancer profiles of the cuproptosis gene set
2022 · External reference
Cuprotosis-related signature predicts overall survival in clear cell renal cell carcinoma
10.3389/fcell.2022.922995 · 2022 · External reference
10.1016/j.semcancer.2021.03.008
10.1016/j.semcancer.2021.03.008 · External reference
Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment
10.1038/s41467-022-32570-z · 2022 · External reference
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
10.1016/j.pharmthera.2018.09.008 · 2019 · External reference
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
2019 · External reference
10.1016/j.addr.2017.04.010
10.1016/j.addr.2017.04.010 · External reference
10.1016/j.trecan.2019.10.007
10.1016/j.trecan.2019.10.007 · External reference
10.1038/s41577-018-0044-0
10.1038/s41577-018-0044-0 · External reference
10.1016/j.immuni.2021.11.015
10.1016/j.immuni.2021.11.015 · External reference
10.1016/j.omtn.2023.09.003
10.1016/j.omtn.2023.09.003 · External reference
10.1016/j.csbj.2023.04.004
10.1016/j.csbj.2023.04.004 · External reference
10.1158/0008-5472.can-15-1538
10.1158/0008-5472.can-15-1538 · External reference
The pyroptosis-related risk genes APOBEC3D, TNFRSF14, and RAC2 were used to evaluate prognosis and as tumor suppressor genes in breast cancer
2022 · External reference
NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study
10.1186/1471-2407-12-24 · 2012 · External reference
